Phuong Dang

2.4k total citations · 1 hit paper
31 papers, 1.6k citations indexed

About

Phuong Dang is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Phuong Dang has authored 31 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Hematology, 21 papers in Genetics and 12 papers in Rheumatology. Recurrent topics in Phuong Dang's work include Chronic Myeloid Leukemia Treatments (25 papers), Chronic Lymphocytic Leukemia Research (20 papers) and Eosinophilic Disorders and Syndromes (12 papers). Phuong Dang is often cited by papers focused on Chronic Myeloid Leukemia Treatments (25 papers), Chronic Lymphocytic Leukemia Research (20 papers) and Eosinophilic Disorders and Syndromes (12 papers). Phuong Dang collaborates with scholars based in Australia, United States and Switzerland. Phuong Dang's co-authors include Timothy P. Hughes, Deborah L. White, Verity A Saunders, Paul W. Manley, Jane R. Engler, Andrew C.W. Zannettino, Stephanie Zrim, Junia V. Melo, David T Yeung and Susan Branford and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Phuong Dang

29 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

2013 508 citations David M. Ross, Susan Branford et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Phuong Dang Australia	12	1.4k	1.1k	643	334	178	31	1.6k
Anna Turkina Russia	17	1.2k 0.8×	1.0k 0.9×	544 0.8×	296 0.9×	234 1.3×	134	1.5k
P. Le Coutre Germany	5	1.3k 1.0×	1.1k 1.0×	673 1.0×	245 0.7×	143 0.8×	5	1.6k
Albert Hoenekopp Switzerland	10	1.6k 1.2×	1.3k 1.2×	845 1.3×	253 0.8×	161 0.9×	21	1.8k
Philippe Rousselot France	16	2.0k 1.5×	1.7k 1.5×	1.0k 1.6×	365 1.1×	253 1.4×	31	2.3k
Lydia Wunderle Germany	9	1.2k 0.9×	739 0.6×	538 0.8×	262 0.8×	193 1.1×	17	1.5k
Philipp D. le Coutre Germany	23	2.3k 1.6×	1.9k 1.7×	1.2k 1.9×	449 1.3×	194 1.1×	72	2.5k
P. Rae United States	6	984 0.7×	679 0.6×	476 0.7×	279 0.8×	412 2.3×	8	1.4k
Devendra Hiwase Australia	20	944 0.7×	489 0.4×	174 0.3×	296 0.9×	378 2.1×	107	1.3k
Athena Countouriotis United States	14	1.6k 1.2×	1.4k 1.3×	943 1.5×	323 1.0×	178 1.0×	21	1.9k
Joanna Góra‐Tybor Poland	18	594 0.4×	733 0.6×	186 0.3×	218 0.7×	291 1.6×	82	1.2k

Countries citing papers authored by Phuong Dang

Since Specialization

Citations

This map shows the geographic impact of Phuong Dang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phuong Dang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phuong Dang more than expected).

Fields of papers citing papers by Phuong Dang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Phuong Dang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phuong Dang. The network helps show where Phuong Dang may publish in the future.

Co-authorship network of co-authors of Phuong Dang

This figure shows the co-authorship network connecting the top 25 collaborators of Phuong Dang. A scholar is included among the top collaborators of Phuong Dang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Phuong Dang. Phuong Dang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kok, Chung Hoow, Yazad Irani, Jade Clarson, et al.. (2024). CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinib. PubMed. 1(2). 100014–100014. 1 indexed citations

Dang, Phuong, et al.. (2024). Toward Emotion Recognition and Person Identification Using Lip Movement from Wireless Signals: A Preliminary Study. 1–5. 1 indexed citations

Dang, Phuong, et al.. (2024). Towards Sustainable Products and Services: The Influences of Traditional Costumes in Promoting Sustainable Fashion. Sustainability. 16(22). 9800–9800. 1 indexed citations

Kok, Chung Hoow, Verity A Saunders, Phuong Dang, et al.. (2023). Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib. Blood Cancer Journal. 13(1). 143–143. 1 indexed citations

Ngo, Thang, et al.. (2023). VISUAL COMMUNICATION DESIGN AND SUSTAINABILITY: REFLECTIONS FROM A PILOT COURSE WITH DESIGN FOR SUSTAINABILITY METHODS AND TOOLS. INTED proceedings. 1 indexed citations

Pagani, Ilaria S., Naranie Shanmuganathan, Phuong Dang, et al.. (2023). Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy. Blood. 142(25). 2192–2197. 5 indexed citations

Tiong, Ing Soo, Phuong Dang, Kate E. Jones, et al.. (2022). Clinically relevant variation in FLT3-ITD quantitation as a result of PCR cycle number and ITD insertion size. Pathology. 55(1). 71–76. 1 indexed citations

Pagani, Ilaria S., Phuong Dang, Verity A Saunders, et al.. (2020). Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia. Leukemia & lymphoma. 61(10). 2527–2529. 2 indexed citations

Kok, Chung Hoow, David T Yeung, Lu Liu, et al.. (2019). Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib. Blood Advances. 3(10). 1610–1621. 23 indexed citations

10.

Pagani, Ilaria S., Phuong Dang, Verity A Saunders, et al.. (2019). Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission. Leukemia. 34(4). 1052–1061. 31 indexed citations

11.

Eadie, Laura N, Phuong Dang, Jarrad M. Goyne, Timothy P. Hughes, & Deborah L. White. (2018). ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells. PLoS ONE. 13(1). e0192180–e0192180. 20 indexed citations

12.

Ross, David M., Ilaria S. Pagani, Naranie Shanmuganathan, et al.. (2018). Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. Leukemia. 32(12). 2572–2579. 56 indexed citations

13.

Pagani, Ilaria S., Phuong Dang, Jarrad M. Goyne, et al.. (2018). BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia. Haematologica. 103(12). 2026–2032. 25 indexed citations

14.

Sadras, Teresa, Susan L. Heatley, Chung Hoow Kok, et al.. (2017). Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions. Cancer Letters. 408. 92–101. 17 indexed citations

15.

Kok, Chung Hoow, Verity A Saunders, Jarrad M. Goyne, et al.. (2017). Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells. Haematologica. 102(5). 843–853. 11 indexed citations

16.

White, Deborah L., Verity A Saunders, Amity Frede, et al.. (2009). The Functional Activity of the OCT-1 Protein Is Predictive of Molecular Response and Survival in CP-CML Patients Treated with Imatinib: A 5 Year Update of the TIDEL Trial.. Blood. 114(22). 507–507. 2 indexed citations

17.

Hiwase, Devendra, Verity A Saunders, D. Hewett, et al.. (2008). Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications. Clinical Cancer Research. 14(12). 3881–3888. 154 indexed citations

18.

White, Deborah L., Verity A Saunders, Phuong Dang, et al.. (2007). Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 110(12). 4064–4072. 244 indexed citations

19.

Hiwase, Devendra, Deborah L. White, Verity A Saunders, et al.. (2007). In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis.. Blood. 110(11). 1937–1937. 5 indexed citations

20.

Keller, Steven M., Louise Ryan, Lawrence R. Coia, et al.. (1998). High dose chemoradiotherapy followed by esophagectomy for adenocarcinoma of the esophagus and gastroesophageal junction. Cancer. 83(9). 1908–1916. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact